PRE ECLAMPSIA & ECLAMPSIA

By Dr Shanza auroojPost Graduate Trainee

Gynea unit IIISPH Quetta

Classification of Hypertensive Disorders in Pregnancy 

Gestational Hypertension Pre-eclampsia Chronic hypertesion essential secondary Pre-eclampsia superimposed on chronic

hypertension Eclampsia 

DEFINATIONS: Gestational hypertension new hypertension presenting after 20 weeks without significant proteinuria and features of

preeclampsia,BP levels return to normal within 3 months postpartum

Pre-eclampsia is new hypertension presenting after 20 weeks with

significant proteinuria. Severe pre-eclampsia is pre-eclampsia with severe hypertension and/or

with symptoms,and/or biochemical and/or haematological impairment. after 20 weeks

 

Eclampsia is a convulsive condition associated with pre-eclampsia

Chronic hypertension is hypertension that is present before 20 weeks characterized by a BP of 140/90 mmHg or greater . It can be primary or secondary in aetiology

Pre-eclampsia superimposed on chronic hypertension is hypertension present before 20 weeks with development of symptoms of pre-eclampsia after 20 weeks

 

Significat proteinuria excretion of 300mg/24hr of urinary proteins in 24hr urine collection or a concentration of 30mg/dl >1+ on dipstick in atleast two random urine samples collected 4 to 6 hrs apart

Grades of hypertensionMild hypertension diastolic blood pressure 90–99 mmHg, systolic blood

pressure140–149 mmHg.Moderate hypertension diastolic blood pressure 100–109 mmHg, systolic blood

pressure 150–159 mmHg.Severe hypertension diastolic blood pressure 110 mmHg or greater, systolic

bloodpressure 160 mmHg or greater

What is pre-eclampsia? 

A pregnancy specific syndrome characterized by

variable degrees of placental dysfunction and a maternal response featuring systemic infammation

PATHOPYSIOLOGY

The etiology of preeclampsia is unknown. However, placental delivery reverses the symptoms of preeclampsia, suggesting that the placenta has a controlling role in the condition. Additionally, women with increased placental tissue for gestational age, such as hydatiform moles and twin pregnancies, have an increased incidence of preeclampsia.

Several theories attempt to explain the pathophysiology of preeclampsia

Most popular theory holds that improper placental development results in placental vascular endothelial dysfunction and a relative uteroplacental insufficiency. The vascular endothelial dysfunction results in increased permeability, hypercoagulability, and diffuse vasospasm

Placental pathology

Changes in normal pregnancy In normal pregnancy spiral arteries of the placental bed undergoes

a series of physiological changes cytotrophoblasts replace the endothelial cells in the spiarl arteries

resulting in destruction of medial elastic and muscular tissue,these physiological changes reach the inner third of myometrium and create a low vascular arterioler system that allows a dramatic increase in blood supply necessary to serve the growing fetus.The end result is that 100 to 120 spiral arteries are converted into dilated inelastic tubes without maternal vasomotor control

Changes in preeclampsia In pre-eclampsia about half to 2/3rd of spiral arteries escape this

transformation ,in these arteries the myometrial segment remain anatomically intact,do not dilate,many vessels are occluded by fibrinoid material and exhibit adjacent foam cell invasion (atherosis).Atherosis and thrombosis leads to microinfarcts in placenta and are responsible for abruption due to decidual necrosis,separation and hemmorhage.

Maternal organ system involvement

Cardiovuscular system Severe pre-eclampsia is characterized by vasoconstriction and a leaky

microcirculation,with extravasation of fluid in E.C.S and relative hypovolemia leading to hemoconcentration,edema and swelling often facial particularly peroorbital edema in contrast to physiological pedal edema

 Renal system Primary renal manifestation of endothelial cell activation is inflammatory

swelling of glomeruler endothelial capillaries causing an increase in the renal vascular resistance with a decrease in the renal blood flow resulting in decreased GFR and EFRP complicating to ANURIA or OLIGURIA leading to ARF.

The first change in the renal system involvement is tubular dysfunction resulting in decreased uric acid clearance from the body and hyperuicemia,the next event is proteinuria due to loss of negative charge from the GBM ,finally there is rise in levels of urea and creatinine . Proteinuria further leads to hypoalbunemia with extravasation of fluid in ECS resulting in genearilzed edema and,ascites,pleural effusion,pulmonary,cerebral and laryngeal edema.

 

Abnormal hemostasis Platelet activation a feature of normal pregnancy is exaggerated

in pre-eclampsia as sysytemic endothelial cell activation cause platelet adherence to site of endothelial damage.Platelets consumption result in thrombocytopenia while platelet adherence leads to formation of microthrombi effecting microcirculation leading to increased intravuscuar coagulation with a rise in fibrin degradation products and hemolysis of RBC’s in microvessels leading to HELLP syndrome.

 HELLP syndrome It is Hemolysis,elevated liver enzymes and low platelets

caused by abnormal hemostasis and liver involvement due to excessive fibrinogen deposition in hepatic sinusoids also obstructing blood flow leading to hepatic capsular distension and epigastric pain,nausea,vomiting. It may complicate to subcapsular hematoma and liver rupture presenting with severe epigastric pain,shoulder pain,shock, hemoperitoneum,respiratory difficulties or pleural effusion.

 

Risk factors Nulliparity extremes of maternal age multifetal gestation pre-eclampsia in a previous pregnancy family history chronic hypertension or renal disease chronic infections maternal low birth weight obesity and insulin resistance Pre-gestational DM smoking maternal genes chronic inflammatory conditions like (SLE & RA) Anti-phospholipid antibody syndrome molar pregnancy

Symptoms of pre-eclampsia  severe headache problems with vision, such as blurring or flashing before the eyes severe pain just below the ribs vomiting sudden swelling of the face, hands or feet. Seizures (eclampsia) grand mal in character with tonic clonic phases Physical signs: Asymptomatic hypertension is discovered on routine prenatal

examination. Diffuse edema has a high specificity for preeclampsia. Neurologic findings such as papilledema and hyperreflexia must be

addressed quickly, as they can herald the onset of eclampsia. Petechiae and bruising could suggest coagulopathy. Right upper quadrant or mid epigastric tenderness develops as a

result of hepatocellular necrosis.  

Complications

Maternal complications

Abruption placenta DIC/HELLP syndrome Acute Renal Failure Eclampsia Liver failure & Hemmorhage Stroke Death Long term cardiovascular morbidity Neonatal complications

Preterm delivery IUGR Hypoxic neurological injury Perinatal death Low birth weight with long term morbidity 

DIFFERENTIALS 　   Disseminated Intravascular Coagulation Fatty Liver Cholecystitis Perforated peptic ulcer Systemic Lupus Erythematosus Thrombotic Thrombocytopenic Purpura

LAB STUDIES

BASELINE• CBC• BLOOD GROUP• HEPATITUS B & C

Urine analysis of a clean catch specimen Proteinuria 2+ or higher is significant and warrants further evaluation to rule out preeclampsia. A 24-hour urine collection with more than 300 mg of protein

RFT’s• UREA > 40 mmol/l or >11 mg/dl• Creatinine>1 mg/dl• Serum uric acid levels >6.3 mg/dl

LFT’s• AST or ALT >50 IU/L• Biluribin >25 IU/L

Clotting profile• PT/APTT• Fibrin degradation products

IMAGING STUDIES

Ultrasound

Confirmation of normal fetal development is important and standard prenatal care in all pregnancies.Points to study in US are

Fetal biometry(AC,HC,BPD,FL) AOL & estimated fetal weight Placental localization

Doppler velocimetry

Screening test in first trimester to detect changes in spiral arteries and is considered abnormal if there is an early diastolic notch or high RI

 

Management options: Management can be discussed under following headings Prevention Antihypertensive treatment Anticonvulsant treatment Steroids for lung maturation Fluid balance Mode and timing of birth Fetal monitoring in high risk patient Intrapartum care Postnatal monitoring,treatment and

investigations Breast feeding Advice and follow up care 

Primary prevention

Pre pregnancy weight control in high risk patients Vitamin B and folate supplementations Cessation of smoking Control of Hypertension in women having chronic hypertension Control of sugar levels in women having Diabetes pre-pregnancy Secondary prevention  Calcium supplementations:it reduces parathyroid and renin release

thereby reducing intracellular calcium and smooth muscle contractility,the ideal patient is the one who is obese with raised BP at booking visit

Antiplatelet agents:low dose aspirin is recommended in high risk patients as it inhibits thromboaxane synthesis thus altering the balance in favor of PGI usually before 23 weeks and therefore helps in proper placentation in a dose of 75mg OD starting from 12 weeks until birth

For other agents like Mg and Zinc supplements,fish oil,salt restriction, antioxidants like vitamin C,E there is insufficient data to recommend their use in primary prevention

 

ANTIHYPERTENSIVES…when to give?Degree ofhypertension

Mild hypertension(140/90 to 149/99 mmHg)

Moderate hypertension(150/100 to 159/109 mmHg

Severe hypertension(160/110 mmHg orhigher)

Admit to hospital NO YES YES

Treat NO With oral labetalol† asfirst-line treatment tokeep:diastolic bloodpressure between80–100 mmHgsystolic bloodpressure less than150 mmHg

With oral labetalol† asfirst-line treatment tokeep:diastolic bloodpressure between80–100 mmHgsystolic bloodpressure less than150 mmHg

Measurebloodpressure

At least four times aday

At least four times a day More than four times aday, depending onclinical circumstances

Test forproteinuria

Do not repeatquantification ofproteinuria

Do not repeatquantification ofproteinuria

Do not repeatquantification ofproteinuria

Blood tests Monitor using thefollowing tests twice aweek: kidney function,electrolytes, full bloodcount, transaminases,bilirubin

Monitor using thefollowing tests threetimes a week: kidneyfunction, electrolytes, fullblood count,transaminases, bilirubin

Monitor using thefollowing tests threetimes a week: kidneyfunction, electrolytes, fullblood count,transaminases, bilirubin

Choice of antihypertensives

Only offer women with pre-eclampsia antihypertensive treatment other than labetalol after considering side-effect profiles for the woman, fetus and newborn baby.

Alternatives include methyldopa† and nifedipine†

Adult Dose 5-10 mg IV; repeat 20min to maximum of 60 mg

ContraindicationsDocumented

hypersensitivity, dissecting aortic

aneurysm, mitral valve rheumatic heart disease

Interactions:MAO inhibitors and beta-

blockers may increase hydralazine toxicity;

pharmacological effects of hydralazine may be

decreased by indomethacin

Adverse effects headache, flushing,

overshoot hypotension, peripheral edema,

implicated in myocardial infarction;

Pregnancy C (safety not established)

Hydralazine (Apresoline) -- First-line therapy against preeclamptic hypertension in past decades. Decreases systemic resistance through direct vasodilation of arterioles resulting in

reflex tachycardia..

Labetalol (Normodyne) -- Second-line therapy that produces vasodilatation and

decrease in systemic vascular resistance. Has alpha-1 and beta antagonist effects and beta-2

agonist effects. Has more rapid onset than hydralazine and less overshoot hypotension.

Adult Dose 50-100 mg IV; repeat 30min to a

maximum of 300 mgPreganacy C (safety not

established)

ContraindicationsDocumented

hypersensitivity, cardiogenic shock, pulmonary edema,

bradycardia, heart block, uncompensated CHF,

reactive airway disease

Precautions Caution in impaired hepatic function;

discontinue therapy if there are signs of liver

dysfunction; in elderly patients, a lower response rate and higher incident of toxicity may be observed;

intensified bronchospasms, heart block, CHF

Methyldopa_lowers BP by reducing overall sympathetic outflow,effective in mild to

moderate hypertension but a fall in BP occurs only 4 to 8 hrs after

an oral dose

Adult dose loading dose of 500-1000mg is

followed by 250-750mg four times

a day

Pregnancy C safety

not established

Adverse effects fetal

bradycardia,maternal

hypotension,flushing headache ,

depression,vomiting,palpitation

Nifedipine Potent direct vasodilators,rapid onset of action,safe and effective Adverse effects severe headache,hypotension and flushing

Nitroprusside (Nitropress) -- Used when hydralazine and labetalol are ineffective. Reduces peripheral resistance by acting directly on arteriolar and venous smooth muscle.

Pregnancy C - Safety for use during pregnancy has not been established.

adverse effects of nitroprusside include tinnitus, blurred vision, altered mental status, hypotension, and methemoglobinemia

Diazoxide powerful direct vasodilator mini-bolus dose of 15mg of diazoxide is as effective as

hydralazine with less side effects 

Anticonvulsant therapy:

When to use? If a woman in a critical care setting who has

severe hypertension or severe pre-eclampsia has or previously had an eclamptic fit, give intravenous magnesium sulphate*.

Consider giving intravenous magnesium sulphate* to women with severe preeclampsia who are in a critical care setting if birth is planned within 24 hours

If considering magnesium sulphate* treatment, use the following as features of severe pre-eclampsia:

severe hypertension and proteinuria or mild or moderate hypertension and proteinuria with one or

more of the following:1. symptoms of severe headache2. problems with vision, such as blurring or flashing before the

eyes3. severe pain just below the ribs or vomiting4. papilloedema5. signs of clonus (≥3 beats)6. liver tenderness7. HELLP syndrome8. platelet count falling to below 100 x 109 per litre9. abnormal liver enzymes (ALT or AST rising to above 70 iu/litre).

Use the Collaborative Eclampsia Trial[2] regimen for administration of magnesium sulphate*:

loading dose of 4 g should be given intravenously over 5 minutes, followed by an infusion of 1 g/hour maintained for 24 hours

recurrent seizures should be treated with a further dose of 2–4 g given over 5 minutes.

Do not use diazepam, phenytoin as an alternative to magnesium sulphate* in women with eclampsia.

(NICE GUIDELINE)

Mg sulphate dosage schedule for severe pre-eclampsia and

eclampsia

Continous intravenous infusion Give 4-6 gm of loading dose in 100 ml of IV fluid

administered over 15-20 min Begin 2 gm/h in 50 ml of IV maintainance infusion Measure serum magnesium level at 4-6 hrs and adjust

between 4-7 meq/l Magnesium sulfate is discontinued 24 hrs after delivery

Intermittent intramuscular injections

Give loading dose of 4 g of magnesium sulfate as a 20% solution intravenously at a rate of 1g/min

Follow with 10g of magnesium sulfate ,one half(5 g) injected deeply in the upper outer quadrant of both buttocks using a 3-inch long 20 guage needle

If convulsions persist after 15 minutes give 2 gm more IV as a 20%solution as 1g/min.,for a large women 4 gm can be given slowly and safely

Every 4 hrs thereafter give 5 gm of Mg sulphate in alternate buttocks after assuring

1. the patellar reflex is present2. Respirations are not depressed3. Urine output during the previous 4 hrs exceed 400ml Discontinue 24 hrs after delivery (William obstetrics)

Drug Category: Anticonvulsants Drug Name

Magnesium Sulfate – First-line therapy for seizure prophylaxis. Antagonizes calcium channels of smooth muscle. Adult Dose 4-6 g IV over 20 min, with maintenance of 1-2 g/h Contraindications Hypermagnesemia, heart block, severe hepatitis

renal disease, Addison disease, myocardial damage Overdose calcium gluconate, 10-20 mL IV of 10%; serum

magnesium level should be checked one hour after initiation of therapy with goal of therapeutic level of 4-7 mEq/L

Phenytoin (Dilantin) -- The major site of action is the motor cortex where it acts by preventing the spread of seizure activity.

Indicated for eclampsia.Adult Dose 20 mg/kg IV infused at a rate of 12.5 mg/min, not to exceed

1500 mg/24h Contraindications Documented hypersensitivity, sinoatrial block, sinus

bradycardia, Adam-Stokes syndrome Pregnancy D - Unsafe in pregnancy

Diazepam (Valium) -- For treatment of seizures resistant to magnesium sulfate. Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA.

Indicated for status epilepticus in eclamptic patients. Adult Dose 5-10 mg IV, repeat to total of 30 mg Contraindications Documented hypersensitivity; narrow angle

glaucoma Fetal respiratory depression, fetal heart beat variability, maternal

respiratory depression, delivery of fetus imminent Pregnancy D - Unsafe in pregnancy PrecautionsMonitor respiratory status during administrati on

Corticosteroids for fetal lung maturation

• If birth is considered likely within 7 days in women with pre-eclampsia:

give two doses of betamethasone* 12 mg intramuscularly 12 hours apart in women between 24 and 34 weeks

consider giving two doses of betamethasone* 12 mg intramuscularly12 hours apart in women between 35 and 36 weeks.

Corticosteroids to manage HELLP syndromeDo not use dexamethasone or betamethasone for the treatment of

HELLP syndrome.

Fluid balance and volume expansion

Do not use volume expansion in women with severe pre-eclampsia unless hydralazine is the antenatal antihypertensive.

In women with severe pre-eclampsia, limit maintenance fluids to 80 ml/hour unless there are other ongoing fluid losses (for example, haemorrhage).

 

TIMING OF BIRTH Manage pregnancy in women with pre-eclampsia

conservatively (that is, do not plan same-day delivery of the baby) until 34 weeks.

Consultant obstetrician should document in the woman's notes the maternal (biochemical, haematological and clinical) and fetal thresholds for elective birth before 34 weeks in women with pre-eclampsia.

Consultant obstetrician should write a plan for antenatal fetal monitoring during birth.

Before 34 weeks Offer birth to women with pre-eclampsia before 34 weeks,

after discussion with neonatal and anaesthetic teams and a course of corticosteroids has been given if:

severe hypertension develops refractory to treatment maternal or fetal indications develop as specified in the

consultant plan

After 34 weeks Recommend birth for women who have pre-eclampsia

with severe hypertension after 34 weeks when their blood pressure has been controlled and a course of corticosteroids has been completed (if appropriate).

Between 34+0 to 36+6 weeks Offer birth to women who have pre-eclampsia with mild

or moderate hypertension at 34+0 to 36+6 weeks depending on maternal and fetal condition,risk factors and availability of neonatal intensive care.

At 37+0 weeks Recommend birth within 24–48 hours for women who

have pre-eclampsia with mild or moderate hypertension after 37+0 weeks (nice guideline)

 

Fetal monitoring Carry out cardiotocography at diagnosis of severe

gestational hypertension or pre-eclampsia. If conservative management of severe gestational

hypertension or pre-eclampsiais planned, carry out all the following tests at diagnosis:

• ultrasound for fetal growth and amniotic fluid volume assessment

• umbilical artery doppler velocimetry. If the results of all fetal monitoring are normal in

women with severe gestational hypertension or pre-eclampsia, do not routinely repeat cardiotocography more than weekly.

In women with severe gestational hypertension or pre-eclampsia, repeat cardiotocography if if any of the following occur:

the woman reports a change in fetal movement vaginal bleeding abdominal pain deterioration in maternal condition.

In women with severe gestational hypertension or pre-eclampsia, do not routinely repeat ultrasound for fetal growth and amniotic fluid volume assessment or umbilical artery doppler velocimetry more than every 2 weeks.

If the results of any fetal monitoring in women with severe gestational hypertension or pre-eclampsia are abnormal, tell a consultant obstetrician

For women with severe gestational hypertension or pre-eclampsia, write a careplan that includes all of the following:

o the timing and nature of future fetal monitoringo fetal indications for birth and if and when corticosteroids

should be giveno when discussion with neonatal paediatricians and obstetric

anaesthetists should take place and what decisions should be made

Intrapartum care Blood pressureDuring labour, measure blood pressure:• hourly in women with mild or moderate hypertension• continually in women with severe hypertension.• Continue use of antenatal antihypertensive treatment during labour.

Haematological and biochemical monitoringDetermine the need for haematological and biochemical tests during labour

inwomen with mild or moderate hypertension using the same criteria as in theantenatal period even if regional analgesia is being considered.

Care during epidural analgesia Do not preload women who have severe pre-eclampsia with intravenous

fluidsbefore establishing low-dose epidural analgesia and combined spinal epiduralanalgesia.

Management of the second stage of labour

Do not routinely limit the duration of the second stage of labour: in women with stable mild or moderate hypertension or if blood pressure is controlled within target ranges in women with severe hypertension.

Recommend operative birth in the second stage of labour for women with severe hypertension whose hypertension has not responded to initial treatment.

Postnatal investigation,

monitoring and treatment (including

afterdischarge from critical

care)Blood pressureIn women with pre-eclampsia who did not take antihypertensive treatment

and have given birth, measure blood pressure: at least four times a day while the woman is an inpatient at least once between day 3 and day 5 after birth on alternate days until normal if blood pressure was abnormal on days

3–5.In women with pre-eclampsia who did not take antihypertensive treatment

and have given birth, start antihypertensive treatment if blood pressure is 150/100 mmHg or higher.

Ask women with pre-eclampsia who have given birth about severe headache and epigastric pain each time blood pressure is measured.

In women with pre-eclampsia who took antihypertensive treatment and have given birth, measure blood pressure:

o at least four times a day while the woman is an inpatient

o every 1–2 days for up to 2 weeks after transfer to community care until the woman is off treatment and has no hypertension.

For women with pre-eclampsia who have taken antihypertensive treatment and have given birth:

continue antenatal antihypertensive treatment consider reducing antihypertensive treatment if their

blood pressure falls below 140/90 mmHg

reduce antihypertensive treatment if their blood pressure falls below 130/80 mmHg.

If a woman has taken methyldopa† to treat pre-eclampsia, stop within 2 days of birth.

Offer women with pre-eclampsia who have given birth transfer to community care if all of the following criteria have been met:

1. there are no symptoms of pre-eclampsia2. blood pressure, with or without treatment, is 149/99 mmHg or

lower3. blood test results are stable or improving. Write a care plan for women with pre-eclampsia who

have given birth and are being transferred to community care that includes all of the following:

• who will provide follow-up care, including medical review if needed

• frequency of blood pressure monitoring• thresholds for reducing or stopping treatment• indications for referral to primary care for blood pressure review• self-monitoring for symptoms.

Offer women who have pre-eclampsia and are still on antihypertensive treatment 2 weeks after transfer to community care a medical review.

Offer all women who have had pre-eclampsia a medical review at the postnatal review (6–8 weeks after the birth).

Offer women who have had pre-eclampsia and who still need antihypertensive treatment at the postnatal review (6–8 weeks after the birth) a specialist assessment of their hypertension.

Haematological and biochemical monitoring

In women who have pre-eclampsia with mild or moderate hypertension, measure platelet count, transaminases and serum creatinine 48–72 hours after birth

do not repeat platelet count, transaminases or serum creatinine measurements if results are normal at 48–72 hours.

If biochemical and haematological indices are improving but stay within the abnormal range repeat measurements as clinically indicated and at the postnatal review (6–8 weeks after the birth).

If biochemical and haematological indices are not improving , repeat platelet count, transaminases and serum creatinine measurements as clinically indicated.

carry out a urinary reagent-strip test at the postnatal review (6–8 weeks after the birth).

Offer women who had pre-eclampsia and still have proteinuria (1+ or more) at the postnatal review (6–8 weeks after the birth) a further review at 3 months after the birth to assess kidney function and consider offering them a referral specialist kidney assessment.

Breastfeeding

In women who still need antihypertensive treatment in the postnatal period,avoid diuretic treatment for hypertension if the woman is breastfeeding or expressing milk.

Tell women who still need antihypertensive treatment in the postnatal period that the following antihypertensive drugs have no known adverse effects on babies receiving breast milk:

labetalol nifedipine enalapril captopril atenolol metoprolol Tell women who still need antihypertensive treatment in the postnatal

period that there is insufficient evidence on the safety in babies receiving breast milk of the following antihypertensive drugs:

• ARBs• amlodipine• ACE inhibitors other than enalapril† and captopril†. Assess the clinical wellbeing of the baby, especially adequacy of feeding,

at least daily for the first 2 days after the birth.

Advice and follow-up care at transfer to community

care

Long-term risk of cardiovascular disease increased later in life Long-term risk of end-stage kidney disease Tell women with a history of pre-eclampsia who have

no proteinuria and no hypertension at the postnatal review (6–8 weeks after the birth) that although the relative risk of end-stage kidney disease is increased the absolute risk is low and no further follow-up is necessary

Thrombophilia and the risk of pre-eclampsiaDo not routinely perform screening for thrombophilia

in women who have had pre-eclampsia.

Risk of recurrence of hypertensive disorders of pregnancy

Tell women who had gestational hypertension that their risk of developing:

• gestational hypertension in a future pregnancy ranges from about 16 to 47%

• pre-eclampsia in a future pregnancy ranges from 2 to 14%

Tell women who had pre-eclampsia that their• risk of gestational hypertension in a future pregnancy ranges

from about 13 to 53%• pre-eclampsia in a future pregnancy is up to about (16%)• pre-eclampsia in a future pregnancy is about (25%) pregnancies

if their preeclampsia was complicated by severe pre-eclampsia, HELLP syndrome or eclampsia and led to birth before 34 weeks, and about (55%) pregnancies if it led to birth before 28 weeks.

Inter-pregnancy interval and recurrence of hypertensive disorders of pregnancy

Tell women who have had pre-eclampsia that there is no additional risk of recurrence with inter-pregnancy interval up to 10 years

Body mass index and recurrence of hypertensive disorders of pregnancy

Advise women who have had pre-eclampsia to achieve and keep a BMI within the healthy range before their next pregnancy (18.5–24.9 kg/m2)

 

THANK YOU